Mattawan, Michigan – MPI Research today announced that its board of directors has named Robert H. DeWit, PhD, DABT, as president, effective immediately. DeWit will assume responsibility for the day-to-day operations of the Company.
“The addition of Rob to our executive team will be invaluable as MPI Research continues to grow in the marketplace,” said Lisa Yoder, Director of Communications. “With 25 years of global preclinical drug development and toxicology experience, he is an extremely knowledgeable leader, and highly respected in the industry. We are fortunate to have him on board to help build on our current momentum.”
DeWit joins MPI Research after serving in leadership positions at the Southwest Michigan Innovation Center – first as president and CEO, then as Assistant Dean of the School of Medicine after the Center was transferred to the Western Michigan School of Medicine. DeWit also served as Executive Director and Head of the Chronic Toxicology Center of Emphasis, and as the Site Lead in Kalamazoo for Pfizer Global R&D. His professional experience also includes 20 years of various scientific and leadership positions within Parke-Davis, The Upjohn Company, Pharmacia and Pfizer.
DeWit is no stranger to MPI Research, having served on the Company’s Scientific Advisory Board over the last several years. He has also provided a number of leadership training classes at the Company.
“It has been my pleasure to engage with MPI Research in numerous capacities over the years, and I’ve seen the company grow in remarkable ways,” said DeWit. “I’m looking forward to joining the team and being part of the Company’s next stage of growth during this exciting and progressive time in drug and device development.”